Edwards Lifesciences (EW) CVP – Japan & Intercontinental Huimin Wang, Unloaded $529,606 in Stock; Immucell (ICCC)’s Sentiment Is 0.88

April 10, 2018 - By Martha Paddon

Edwards Lifesciences Corporation (NYSE:EW) Logo

Sentiment for Immucell Corp (ICCC)

Immucell Corp (ICCC) investors sentiment decreased to 0.88 in 2017 Q4. It’s down -2.12, from 3 in 2017Q3. The ratio turned negative, as 7 active investment managers started new or increased stock positions, while 8 sold and decreased their equity positions in Immucell Corp. The active investment managers in our database now possess: 678,210 shares, up from 663,729 shares in 2017Q3. Also, the number of active investment managers holding Immucell Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 8 Increased: 3 New Position: 4.

Perritt Capital Management Inc holds 0.38% of its portfolio in ImmuCell Corporation for 154,300 shares. Heartland Advisors Inc owns 199,600 shares or 0.11% of their US portfolio. Moreover, Minerva Advisors Llc has 0.06% invested in the company for 14,559 shares. The Connecticut-based Essex Financial Services Inc. has invested 0.05% in the stock. Essex Investment Management Co Llc, a Massachusetts-based fund reported 35,205 shares.

The stock decreased 0.40% or $0.0301 during the last trading session, reaching $7.4199. About 2,464 shares traded. ImmuCell Corporation (ICCC) has risen 22.33% since April 10, 2017 and is uptrending. It has outperformed by 10.78% the S&P500.

ImmuCell Corporation develops, acquires, makes, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company has market cap of $40.66 million. The firm offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It currently has negative earnings. It is also involved in the development of Mast Out, a Nisin treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens.

Huimin Wang, an insider of Edwards Lifesciences Corp, currently CVP – Japan & Intercontinental a few days ago disclosed a sale with the U.S. SEC. As reported in the legal form, Huimin Wang unloaded 3,800 shares of the public firm, priced at $139.4 per share. $529,606 USD was the sale’s value. The SEC filing’s date was April 6, 2018. It seems she is very active lately as in the last month, she sold additional 3,800 shares of the company, worth $538,992 USD. Mr. Huimin at present owns 81,216 shares, accounting for 0.04% of Edwards Lifesciences Corp’s total market capitalization.

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on April, 24. They expect $1.10 EPS, up 17.02% or $0.16 from last year’s $0.94 per share. EW’s profit will be $231.57 million for 31.22 P/E if the $1.10 EPS becomes a reality. After $0.94 actual EPS reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts 17.02% EPS growth.

The stock decreased 0.10% or $0.14 during the last trading session, reaching $137.37. About 1.21 million shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 44.06% since April 10, 2017 and is uptrending. It has outperformed by 32.51% the S&P500.

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp has $195 highest and $86 lowest target. $133.78’s average target is -2.61% below currents $137.37 stock price. Edwards Lifesciences Corp had 108 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, February 3. The stock has “Buy” rating by Canaccord Genuity on Thursday, February 15. The firm has “Buy” rating given on Thursday, January 4 by Barclays Capital. The firm has “Buy” rating by Bank of America given on Thursday, July 27. Jefferies maintained the stock with “Buy” rating in Thursday, February 1 report. RBC Capital Markets maintained it with “Buy” rating and $130.0 target in Sunday, November 5 report. Canaccord Genuity maintained the shares of EW in report on Sunday, October 8 with “Buy” rating. The rating was maintained by BMO Capital Markets on Wednesday, October 11 with “Buy”. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Sell” rating given on Wednesday, April 27 by Citigroup. The company was downgraded on Tuesday, April 5 by Northland Capital.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $28.92 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 50.88 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patientÂ’s diseased or defective heart valve.

ImmuCell Corporation (NASDAQ:ICCC) Institutional Positions Chart